Close menu




July 10th, 2025 | 07:15 CEST

How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns

  • Biotechnology
  • healthtech
  • Biotech
  • AI
Photo credits: pixabay.com

Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.

time to read: 4 minutes | Author: Armin Schulz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , PANGENOMIC HEALTH INC | CA69842E4031 , PFIZER INC. DL-_05 | US7170811035

Table of contents:


    BioNTech – New momentum in pipeline and partnerships

    BioNTech is currently facing heavy losses, amounting to around EUR 416 million in the first quarter of 2025. This is due to massive investments in research and development, which alone swallowed up over EUR 0.5 billion in Q1. Revenues from the COVID-19 vaccine continue to decline, with sales at just under EUR 183 million, slightly below the previous year's level. Despite the red figures, the balance sheet remains robust. With almost EUR 16 billion in cash and cash equivalents, the Mainz-based company has sufficient financial resources to fund its ambitious plans in oncology and infectious diseases.

    The strategic realignment is in full swing. The billion-dollar deal with Bristol Myers Squibb for the cancer antibody BNT327 not only brings in USD 1.5 billion in fresh capital, but also access to global marketing power. At the same time, the acquisition of mRNA specialist CureVac strengthens the portfolio, particularly in personalized cancer therapies and new vaccine approaches. These partnerships and acquisitions should help BioNTech replace declining COVID revenues with long-term therapy revenues.

    Innovation at BioNTech is increasingly driven by AI. Its proprietary platform, DeepChain, uses complex biological data to accelerate drug design. This is supported by the Company's in-house supercomputer, "Kyber". In everyday laboratory work, the AI assistant "Laila" takes over routine tasks ranging from DNA analysis to equipment monitoring. These tools now permeate the entire pipeline. For investors, BioNTech is demonstrating how it is using its financial strength and technological base to grow beyond its pandemic-era successes. The stock is currently available for EUR 95.80.

    PanGenomic Health – How digitalization and prevention are creating new opportunities

    The US healthcare market is undergoing a digital revolution. Driven by skyrocketing treatment costs, which are the highest in the world at 16% of GDP, and the longevity hype, which is putting sustainable prevention at the center of attention, the digital health sector is growing rapidly. Market volumes of nearly USD 80 billion with double-digit growth rates underscore the potential. Telemedicine, wearables, and AI-powered diagnostics are becoming key solutions that not only give patients more control but also address system inefficiencies. This is where PanGenomic Health comes in, a Canadian innovator that skillfully combines these trends.

    PanGenomic has evolved from a pandemic project to a tech pioneer, offering personalized prevention solutions with its NARA, Mindleap, and MUJN platforms. At its core is AI-powered Nustasis technology, which analyzes genetic profiles, lifestyle data, and neurological biomarkers to generate tailored health recommendations. Unlike pure telemedicine providers, the Company combines digital tools with naturopathic expertise and precision diagnostic services. This hybrid approach, complemented by subscription models and e-commerce, creates scalable revenue streams with manageable development costs.

    The strategic focus on the North American market is particularly relevant for investors. High regular treatment costs and political tailwinds for preventive approaches under the current US administration favor disruptive solutions such as those offered by PanGenomic. With a current market valuation of around CAD 12.5 million and a clearly scalable business model, the Company could benefit in the long term. This is particularly true as it directly addresses the megatrends of self-optimization, data personalization, and cost efficiency. The stock has made a turnaround this year and is currently trading at CAD 0.90.

    Pfizer – On the rise, but with baggage

    Pfizer is showing resilience in the summer of 2025, despite pandemic-related sales continuing to decline. The latest quarterly figures were impressive due to strict cost discipline. Savings of USD 4.5 billion by the end of the year seem achievable. Despite a decline in revenue, mainly due to the slump in Paxlovid, adjusted earnings per share exceeded expectations. The Company is sticking to its forecasts for the year as a whole. Revenues are expected to be between USD 61 billion and USD 64 billion, with earnings per share ranging from USD 2.80 to USD 3.00. The operating margin is clearly benefiting from cost-cutting measures and optimized production.

    Pfizer is focusing on strong therapeutic areas to close the gap left by COVID. Drugs such as Vyndaqel for the heart and its mRNA flu vaccine are showing significant growth. New approvals in oncology and rare diseases are further strengthening the portfolio. The intensive use of artificial intelligence is particularly important. AI accelerates the search for active ingredients from years to just days or months, optimizes production processes, and analyzes vast amounts of patient data for tailored personalized therapies. Partnerships with tech companies are driving this transformation forward.

    Shareholders continue to appreciate the reliable dividend paid to date. The next dividend payment of USD 0.43 per share is due. A yield well above the sector average remains a key argument in favor of the stock. However, there are strong political headwinds. The "Pfizergate" scandal surrounding EU vaccine contracts is damaging the Company's image and could have regulatory consequences. In addition, there are discussions in the US about possible import tariffs and changes to vaccine compensation programs. These uncertainties are an important consideration for investors. Since the beginning of April, the stock has been slowly rising and is currently trading at USD 25.62.


    The integration of artificial intelligence is becoming a key cost reducer and profit driver in the biotechnology sector. BioNTech uses AI platforms such as DeepChain and the supercomputer "Kyber" to accelerate its promising oncology pipeline and overcome losses from the post-COVID era. PanGenomic Health is fully committed to AI-based prevention with its Nustasis technology, which analyzes genetic and lifestyle data to create scalable, personalized healthcare solutions for the lucrative North American market. Pfizer is significantly advancing the use of AI in drug discovery and production to achieve efficiency gains and offset declining COVID-19 revenues with new therapies. Together, they are demonstrating how to profitably tap into the AI-driven billion-dollar markets of personalized medicine.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read

    Commented by Jens Castner on November 18th, 2026 | 05:40 CET

    Treasures from the depths, a slump in the stock market: Lynas, Almonty and Cameco tempt with low share prices

    • Critical raw materials
    • Rare earths
    • Tungsten
    • Uranium
    • Almonty Industries
    • Cameco
    • AI
    • Lynas Rare Earths

    Without rare earths, no electric motors; without tungsten, no defence industry; without uranium, no nuclear power. The West needs these raw materials more urgently than ever and depends on a handful of suppliers that mine in politically stable countries. Yet shares in Lynas Rare Earths, Almonty Industries and Cameco are falling as if there were no shortage – down by one-third to two-thirds from their highs for the year. We have taken a close look at the three producers following their latest quarterly results. One of the shares has reached bargain levels.

    Read